Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High-Grade Gliomas

NCT04485559 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT04485559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04485559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High-Grade Gliomas
Lead sponsor
University of California, San Francisco
Phase
Phase 1
Overall status
Recruiting
Start date
December 9, 2020
Completion date
December 31, 2027
Enrollment
50 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma (hgg), low-grade glioma, recurrent world health organization (who) grade ii glioma